Use of 1-MNA or a pharmaceutically acceptable salt thereof for reducing the risk of cardiovascular disease in a subject whose blood or serum CRP level is less than 10 mg / L. The disclosure also includes rheumatoid arthritis, colon cancer, breast cancer, lung cancer, infection, inflammation, bowel disease, lupus erythematosus, pneumococcal pneumonia, rheumatic fever, tuberculosis, renal failure, amyotrophic lateral sclerosis, or Disclosed is the use of an amount of 1-MNA or a pharmaceutically acceptable salt thereof effective to reduce blood or serum CRP levels for the treatment of diseases such as combinations thereof. [Selection figure] None血中または血清中ＣＲＰレベルが１０ｍｇ／Ｌ未満の被験体において、心血管系疾患のリスクを低減するための１－ＭＮＡまたはその薬学的に許容可能な塩の使用。本開示はまた、慢性関節リウマチ、結腸癌、乳癌、肺癌、感染症、炎症、腸疾患、紅斑性狼瘡、肺炎球菌性肺炎、リウマチ熱、結核、腎不全、筋萎縮性側索硬化症、またはそれらの組み合わせなどの疾患の治療のための、血中もしくは血清中ＣＲＰレベルを低下させるために有効な量の１－ＭＮＡまたはその薬学的に許容可能な塩の使用を開示する。【選択図】なし
